The projected market opportunity is anticipated to be well-distributed across different therapeutic areas.

 As per our research, digital therapeutic solutions for metabolic disorders are likely to capture major share (XX%) of the overall market in 2020. This can be attributed to the fact that majority of the solutions are being developed for people with diabetes. This is followed by the solutions developed for mental health problems and substance use disorders. However, given the fact that a significant number of the solutions are being developed for patients with neurological disorders, solutions for such disorders are anticipated to hold a significant share in the market, in 2030.

 

To Request for Sample report - https://www.rootsanalysis.com/reports/208/request-sample.html

 

Furthermore, according to a recent article published by Evidera, the maximum number of clinical trials (related to digital therapeutics) were conducted for psychiatric indications (25%). These trials also provide a strong evidence supporting digital cognitive behavior therapy’s efficacy in this area. This is followed by trials for evaluating digital therapeutics for cardiovascular (11%), endocrine (10%), addiction (10%), neurology (8%), and respiratory (7%) disorders.

 

In terms of business model adopted, we observed that within digital therapeutics market, majority of the revenues are generated from the sales of the products through B2B channel. This can be attributed to the fact that majority of these digital therapeutic solutions require physicians’ prescription for sale. Further, majority of the companies that have not marketed their solutions rely on this approach to distribute their products to different patient groups.

 

To Request for customize report -

 https://www.rootsanalysis.com/reports/208/request-customization.html

 

In fact, in an interview with the Vice-President of marketing of an industry player, she stated that “The USFDA has approved digital therapeutics as a prescription only product with clearly defined usage parameters. As per the definition, a product can only be called digital therapeutics if it has been built on clinical guidelines and has been able to demonstrate clinical effectiveness. By this measure, it has a therapeutic impact on the body. This means that it must be prescribed by a doctor directly or as part of a combination used with a drug or medical device. It is for this reason that B2B offerings should account for closer to 80-90% of the market currently.”

 In terms of type of geography, North America is anticipated to hold largest share of the current and future market. This can be attributed to the high number of developers offering products in this regions, increased solution prices, and enhanced adoption of novel technologies. This is closely followed by the revenues generated in European regions. It is worth highlighting that market in Asia-Pacific regions is estimated to rise with relatively higher growth rate. As the

 

technology evolves and more players establish their business in Asia-Pacific regions, the market is anticipated to gain momentum in next few years.

 

To request for report, click under - Digital Health Market: Focus on Digital Therapeutics (2nd Edition), 2020-2030

 

You may also be interested in the following titles:

 

1.   Progressive Supranuclear Palsy: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2030

 

2.   Squamous Non-Small Cell Lung Cancer: Pipeline Review, Developer Landscape and Competitive Insights, 2021-2030

 

3.   Polycystic Ovarian Syndrome (PCOS): Pipeline Review, Developer Landscape and Competitive Insights, 2021-2030

 

 

 

Contact Details Ben Johnson

+1 (415) 800 3415

ben.johnson@rootsanalysis.com

 

Roots Analysis

Web: https://www.rootsanalysis.com/

LinkedIn: https://in.linkedin.com/company/roots-analysis

Twitter: https://twitter.com/RootsAnalysis.com

Medium: https://medium.com/@RootsAnalysis

Pinterest: https://in.pinterest.com/RootsanalysisPin/_saved/

Quora: https://rootsanalysisinsights.quora.com/

Comments

Post a Comment

Popular posts from this blog

The microbial contract biomanufacturing market is growing at a CAGR of 8.7%, claims {Roots Analysis}

    The growing pipeline of biologics that can be produced in microbial systems, such as antibody fragments and plasmid-based therapies, is anticipated to offer lucrative opportunities to service providers serving this niche, but growing market segment     London   Roots Analysis has announced the addition of the “ Microbial Contract Biomanufacturing Market, 2020-2030 ” report to its list of offerings.   Despite mammalian cell cultures being the preferred manufacturing approach for biologics, recent advances in microbial fermentation have enabled the development of versatile biomanufacturing systems, which are both robust and cost friendly. Presently, a number of service provider companies claim to offer end-to-end solutions, ranging from product development to commercial production, for microbial biologics. Given the obvious advantages of outsourcing, drug developers are likely to continue relying on contract service providers for various...
Read more

Manufacturing Market Continuous (Small Molecules and Biologics), 2020 – 2030 by Roots Analysis

  Recent advances in the manufacturing technologies have prompted pharmaceutical companies to consider shifting from the traditional multi-step, batch manufacturing processes to faster, and relatively more efficient continuous manufacturing   Roots Analysis is pleased to announce the publication of its recent study, titled, “ Manufacturing Market Continuous (Small Molecules and Biologics), 2020 – 2030 .”   The report features an extensive study of the current market landscape and future opportunities for companies with capabilities in continuous manufacturing (both innovator companies with in-house expertise and contract manufacturers). It features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. In addition to other elements, the study includes: §   A detailed assessment of the overall landscape of companies with capabilities for continuous manufacturing §   Elaborate profiles of some of the key...
Read more

A relatively larger proportion of these firms are headquartered in the US, claims Roots Analysis

  Lately, drug manufacturers have started showing evident interest in modular facilities and using modularity in design approaches owing to the amplified value of smaller production facilities, which are more efficient and flexible. The increased demand for multi-product, multi-purpose, smaller batch size facilities has also prompted equipment manufacturers to revisit their product offerings.   To order this 300+ page report, which features 120+ figures and 130+ tables, please visit this - https://www.rootsanalysis.com/reports/view_document/modular-facilities-flexible-drug-manufacturing-platforms-of-the-future/178.html   The USD xx billion (by 2030) financial opportunity within the modular facilities market has been analyzed across the following segments: ·        Type of Modular Construct  §   Hybrid Skid §   Plug-and-Play §   Skid-Mounted §   Truckable §   Others §   Type of Construc...
Read more